- Reiterating his Buy rating and $13 price target on Dyax (DYAX +2.2%), Needham's Serge Belanger says "Ramucirumab is one of Dyax's LFRP programs for which Dyax would receive 2%-3% sales royalties. We await more detailed data from the REVEL study to update our model."
- Earlier: Eli Lilly's Phase III study meets its primary endpoint.